A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Nanjing Leads Biolabs Co.,Ltd
Genmab
Astellas Pharma Inc
Akeso
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
CStone Pharmaceuticals
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EMD Serono
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
BeiGene
Providence Health & Services
Shanghai Junshi Bioscience Co., Ltd.
Helsinki University Central Hospital
Gilead Sciences
AstraZeneca
AstraZeneca
Tianjin Medical University Cancer Institute and Hospital
Hoffmann-La Roche
National Cancer Centre, Singapore
Shanghai JMT-Bio Inc.
Lumos Pharma
Eli Lilly and Company
Dana-Farber Cancer Institute
ASLAN Pharmaceuticals
SuZhou Stainwei Biotech Inc.
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
PharmaEngine
National Institutes of Health Clinical Center (CC)
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Mayo Clinic
Roswell Park Cancer Institute